Interaction between 3,4‐dichlorophenyl‐propenoyl‐sec.‐butylamine (3,4‐DCPB), an antiepileptic drug, and cytochrome P450 in rat liver microsomes and recombinant human enzymes in vitro

[1]  M. Das,et al.  Species differences between rat and human in vitro metabolite profile, in vivo predicted clearance, CYP450 inhibition and CYP450 isoforms that metabolize benzanthrone: Implications in risk assessment. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[2]  Z. Dong,et al.  Muscone Induces CYP1A2 and CYP3A4 Enzyme Expression in L02 Human Liver Cells and CYP1A2 and CYP3A11 Enzyme Expression in Kunming Mice , 2017, Pharmacology.

[3]  Min-ji Wei,et al.  Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals , 2017, Pharmacogenetics and genomics.

[4]  Chuang Lu,et al.  Identification of cytochrome P450s involved in the metabolism of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1) using human recombinant enzymes and rat liver microsomes in vitro , 2017, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  Rawiwan Maniratanachote,et al.  Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. , 2016, Drug metabolism and pharmacokinetics.

[6]  L. Kang,et al.  Genetic polymorphisms analysis of CYP2D6 in the Uygur population , 2016, BMC Genomics.

[7]  Haifeng Zhao,et al.  Effects of notoginsenoside R1 on CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 activities in rats by cocktail probe drugs , 2016, Pharmaceutical biology.

[8]  Guangzhao Qi,et al.  Functional allele and genotype frequencies of CYP1A2, CYP2B6 and iNOS among mainland Chinese Tibetan, Mongolian, Uygur and Han populations , 2016, Journal of clinical pharmacy and therapeutics.

[9]  G. Pacifici.  Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. , 2016, Current pediatric reviews.

[10]  Yong-long Han,et al.  A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates. , 2015, Biomedical chromatography : BMC.

[11]  D. Ekstein,et al.  Drug interactions involving antiepileptic drugs: Assessment of the consistency among three drug compendia and FDA-approved labels , 2015, Epilepsy & Behavior.

[12]  Qing-Yu Zhang,et al.  Characterization of CYP2B6 in a CYP2B6-Humanized Mouse Model: Inducibility in the Liver by Phenobarbital and Dexamethasone and Role in Nicotine Metabolism In Vivo , 2015, Drug Metabolism and Disposition.

[13]  Ramakrishna Nirogi,et al.  Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  S. Surapureddi,et al.  Regulation of Human CYP2C9 Expression by Electrophilic Stress Involves Activator Protein 1 Activation and DNA Looping , 2014, Molecular Pharmacology.

[15]  R. Kim,et al.  Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. , 2014, Pharmacogenetics and genomics.

[16]  R. Xu,et al.  Evaluation of CYP2C9 Activity in Rats: Use of Tolbutamide Alone and in Combined with Bupropion , 2014, Iranian journal of pharmaceutical research : IJPR.

[17]  H. Adomat,et al.  Identification of human cytochrome P450 enzymes involved in the hepatic and intestinal biotransformation of 20(S)‐protopanaxadiol , 2014, Biopharmaceutics & drug disposition.

[18]  Na Gao,et al.  Inhibition of Baicalin on Metabolism of Phenacetin, a Probe of CYP1A2, in Human Liver Microsomes and in Rats , 2014, PloS one.

[19]  Jennifer E Sager,et al.  Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4 , 2014, Clinical pharmacology and therapeutics.

[20]  S. Heyward,et al.  Metformin Represses Drug-Induced Expression of CYP2B6 by Modulating the Constitutive Androstane Receptor Signaling , 2014, Molecular Pharmacology.

[21]  Lei Zhang,et al.  Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration , 2014, Clinical Pharmacokinetics.

[22]  L. Berry,et al.  Dynamic Modeling of Cytochrome P450 Inhibition In Vitro: Impact of Inhibitor Depletion on IC50 Shift , 2013, Drug Metabolism and Disposition.

[23]  N. Isoherranen,et al.  Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions , 2013, Drug Metabolism and Disposition.

[24]  Ulrich M. Zanger,et al.  Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance , 2013, Front. Genet..

[25]  Zhang Guo-liang.  Enzyme kinetics of novel antiepileptic drug 3,4-dichlorophenyl-propenoyl-sec.-butylamine in rat liver microsomes in vitro , 2013 .

[26]  Z. Desta,et al.  In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. , 2013, Drug metabolism and pharmacokinetics.

[27]  Spencer S. Ericksen,et al.  Preferred Binding Orientations of Phenacetin in CYP1A1 and CYP1A2 Are Associated with Isoform-Selective Metabolism , 2012, Drug Metabolism and Disposition.

[28]  S. Caritis,et al.  A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics , 2012, CPT: pharmacometrics & systems pharmacology.

[29]  Sular nisoldipine.  Pharmacokinetics and Metabolism , 2012 .

[30]  A. D. Rodrigues,et al.  Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro , 2008, Drug Metabolism and Disposition.

[31]  Guo-liang Zhang,et al.  Effect of berberine on hepatocyte proliferation, inducible nitric oxide synthase expression, cytochrome P450 2E1 and 1A2 activities in diethylnitrosamine- and phenobarbital-treated rats. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  W. Chui,et al.  Drug interactions between chemotherapeutic regimens and antiepileptics. , 2008, Clinical therapeutics.

[33]  Guo-liang Zhang,et al.  Effects of Ganoderma lucidum polysaccharide on CYP2E1, CYP1A2 and CYP3A activities in BCG-immune hepatic injury in rats. , 2007, Biological & pharmaceutical bulletin.

[34]  Guo-liang Zhang,et al.  Pharmacokinetics and metabolism of 3,4-dichlorophenyl-propenoyl-sec.-butylamine in rats by high performance liquid chromatography-ion trap mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[35]  M. Lee,et al.  Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. , 2006, Journal of pharmaceutical sciences.

[36]  Anna M. Lee,et al.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein , 2006, British journal of pharmacology.

[37]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[38]  Bu Xiu.  HPLC Determination of 3,4 - Dichlorophenyl - propenoyl -sec. -butylamine(7903) in Rat Plasma , 2004 .

[39]  Guo-liang Zhang,et al.  Pharmacokinetics of ,4-dichlorophenyl-propenoyl-sec. -butylamine (7903) in rats , 2004 .

[40]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[41]  P. Neuvonen,et al.  Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. , 2002, The Journal of pharmacology and experimental therapeutics.

[42]  Y Wang,et al.  Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[43]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[44]  Cao Lg,et al.  [Analysis of the mechanism of anticonvulsant action of 3, 4-dichlorophenyl propenyl isobutylamide (7903)]. , 1982 .

[45]  Y. Pei,et al.  [Analysis of the mechanism of anticonvulsant action of 3, 4-dichlorophenyl propenyl isobutylamide (7903)]. , 1982, Yao xue xue bao = Acta pharmaceutica Sinica.

[46]  Y. Pei,et al.  [The pharmacological actions of 3,4-dichlorophenyl propenoyl isobutylamide on the central nervous system]. , 1982, Yao xue xue bao = Acta pharmaceutica Sinica.

[47]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[48]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.